Elanco Animal Health Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Elanco Animal Health Incorporated on November 11, 2024. The report discloses corporate governance changes effective immediately, specifically the appointment of a new member to the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Board Expansion: The Board of Directors increased its size from 14 to 15 members.
- New Appointment: Stacey Ma, PhD, was appointed to the Board, joining the Class III with a term expiring in 2027.
- Committee Assignment: Dr. Ma was appointed to serve on the Innovation, Science and Technology Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Regarding the new appointment, the Company confirmed there were no arrangements or understandings pursuant to which Dr. Ma was appointed. Additionally, there have been no reportable related party transactions between the Company and Dr. Ma since the beginning of the last fiscal year. Dr. Ma will participate in the standard non-employee director compensation program.
Key Facts for Investor Verification
- Verify the effective date of Dr. Ma's appointment (November 11, 2024) and her term expiration (2027).
- Confirm the new total Board size is 15 members.
- Review the attached press release (Exhibit 99.1) for further details on Dr. Ma's background.
- Note that this filing is a governance update and does not impact current financial statements.